TLDR: Insilico Medicine has showcased its advanced Biology42: Generative Biologics engine, which successfully designed novel peptides targeting the GLP1R receptor for cardiometabolic diseases, including diabetes, within a remarkable 72-hour timeframe. This AI-driven breakthrough yielded potent candidates without prior reference to known binders, demonstrating significant acceleration in drug discovery.
ABU DHABI, UAE – October 29, 2025 – Insilico Medicine, a pioneer in AI-driven drug discovery, has announced a significant advancement in its generative biologics capabilities, demonstrating the rapid design of novel peptides targeting the Glucagon-like peptide-1 receptor (GLP1R) for cardiometabolic diseases, including diabetes. Leveraging its proprietary Biology42: Generative Biologics engine, the company’s R&D team achieved this breakthrough within an unprecedented 72-hour cycle.
The GLP1R is a crucial target in the treatment of cardiometabolic conditions, notably diabetes, with blockbuster drugs like Ozempic modulating this receptor. The urgency for innovative solutions is underscored by alarming statistics: the International Diabetes Federation reported in 2024 that an estimated 589 million adults globally are living with diabetes, with a particularly high prevalence among older adults, affecting one in four individuals aged 65 and above.
In this pioneering study, Insilico’s AI platform generated over 5,000 novel peptides, critically, without referencing any existing GLP1R binders. From this extensive pool, 20 top candidates were meticulously selected for synthesis and subsequent wet-lab evaluation, based on their predicted affinity scores and computed binding energies. The results were highly encouraging: 14 of the tested peptides exhibited biological activity, with three demonstrating single-digit nanomolar potency. This level of performance is typically achieved only after numerous conventional design iterations, highlighting the transformative efficiency of Insilico’s AI approach.
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, emphasized the importance of this achievement, stating, “GLP-1 is a critically important target in the cardiometabolic disease space, which remains a significant global challenge and a key focus for Insilico.” He added, “We are excited to be witnessing rapid progress in this area, made possible by the advanced capabilities of our AI platform. At BIO-Europe 2025, we look forward to sharing further updates on Insilico’s AI-driven pipeline discoveries in cardiometabolic diseases. We also welcome the opportunity to foster in-depth collaborations with industry partners—whether in advancing AI innovation or in the pipeline of novel therapies.”
Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, further elaborated on the technology’s impact: “These findings highlight the transformative potential of Biology42: Generative Biologics in accelerating the discovery and design of novel protein-based therapeutics. Our generative AI platform is designed to create potent, functional biologics from scratch, rapidly and with high precision. This achievement not only demonstrates the strength of our technology in the biologics space but also reinforces Insilico’s ability to drive innovation across a wide range of therapeutic modalities and disease areas.”
Also Read:
- Harbour BioMed Unveils Groundbreaking Generative AI Model for Accelerated Biologics Discovery
- Eli Lilly and Nvidia Forge Alliance to Construct Pharmaceutical Industry’s Most Potent AI Supercomputer for Drug Discovery
This development positions Insilico Medicine at the forefront of leveraging artificial intelligence to expedite the drug discovery process, offering new hope for more efficient and effective treatments for widespread conditions like diabetes, particularly as November 2025 approaches, marking the 19th World Diabetes Day.
